Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Latest Developments in Polypoidal Choroidal Vasculopathy: Epidemiology, Etiology, Diagnosis, and Treatment

Latest Developments in Polypoidal Choroidal Vasculopathy: Epidemiology, Etiology, Diagnosis, and... Downloaded from http://journals.lww.com/apjoo by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/01/2020 CE: M.S.; APJO/APJO-2020-41; Total nos of Pages: 9; APJO-2020-41 REVIEW ARTICLE Latest Developments in Polypoidal Choroidal Vasculopathy: Epidemiology, Etiology, Diagnosis, and Treatment Voraporn Chaikitmongkol, MD , Chui Ming Gemmy Cheung, FRCOphthyz, Hideki Koizumi, MD, PhD§, Vishal Govindahar, MD{, Jay Chhablani, MDjj, and Timothy Y.Y. Lai, MD, FRCOphth yy overview of the current literature in the epidemiology, pathogen- Abstract: Polypoidal choroidal vasculopathy (PCV) is a condition char- esis, genetics of PCV, and recent research findings in the diagno- acterized by multiple, recurrent, serosanguineous pigment epithelial sis and treatment of PCV. detachments, and neurosensory retinal detachments due to abnormal aneurysmal neovascular lesions. It is generally considered as a variant of neovascular age-related macular degeneration, but there are some EPIDEMIOLOGY OF PCV differences between the clinical presentation, natural history, and treat- There is growing evidence of increasing prevalence of age- ment response between patients with PCV and typical neovascular age- related macular degeneration (AMD) worldwide. In Asian popu- related macular degeneration patients. Over the past decade, new research lation-based studies, the prevalence of early AMD and late AMD and technological advancements have greatly improved our understand- has been reported to range from 1.4% to 37.9% http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Asia-Pacific Journal of Ophthalmology Wolters Kluwer Health

Latest Developments in Polypoidal Choroidal Vasculopathy: Epidemiology, Etiology, Diagnosis, and Treatment

Loading next page...
 
/lp/wolters-kluwer-health/latest-developments-in-polypoidal-choroidal-vasculopathy-epidemiology-1Wi7ckjU4E
Publisher
Wolters Kluwer Health
ISSN
2162-0989
eISSN
2475-5028
DOI
10.1097/01.APO.0000656992.00746.48
Publisher site
See Article on Publisher Site

Abstract

Downloaded from http://journals.lww.com/apjoo by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/01/2020 CE: M.S.; APJO/APJO-2020-41; Total nos of Pages: 9; APJO-2020-41 REVIEW ARTICLE Latest Developments in Polypoidal Choroidal Vasculopathy: Epidemiology, Etiology, Diagnosis, and Treatment Voraporn Chaikitmongkol, MD , Chui Ming Gemmy Cheung, FRCOphthyz, Hideki Koizumi, MD, PhD§, Vishal Govindahar, MD{, Jay Chhablani, MDjj, and Timothy Y.Y. Lai, MD, FRCOphth yy overview of the current literature in the epidemiology, pathogen- Abstract: Polypoidal choroidal vasculopathy (PCV) is a condition char- esis, genetics of PCV, and recent research findings in the diagno- acterized by multiple, recurrent, serosanguineous pigment epithelial sis and treatment of PCV. detachments, and neurosensory retinal detachments due to abnormal aneurysmal neovascular lesions. It is generally considered as a variant of neovascular age-related macular degeneration, but there are some EPIDEMIOLOGY OF PCV differences between the clinical presentation, natural history, and treat- There is growing evidence of increasing prevalence of age- ment response between patients with PCV and typical neovascular age- related macular degeneration (AMD) worldwide. In Asian popu- related macular degeneration patients. Over the past decade, new research lation-based studies, the prevalence of early AMD and late AMD and technological advancements have greatly improved our understand- has been reported to range from 1.4% to 37.9%

Journal

The Asia-Pacific Journal of OphthalmologyWolters Kluwer Health

Published: May 1, 2020

References